Page 6 - Suivi à long terme après résection d’un phéochromocytome
P. 6

Kumar et al.




       Références                                            14.  Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: Which test is best?
                                                                JAMA 2002;287:1427-34. https://doi.org/10.1001/jama.287.11.1427
                                                             15.  Perry CG, Sawka AM, Singh R et al. The diagnostic efficacy of urinary fractionated metanephrines measured
        1.  Bravo EL, Tagle R. Pheochromocytoma: State-of-the-art and future prospects. Endocr Rev 2003;24:539-53.   by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) 2007;66:703-8/
          https://doi.org/10.1210/er.2002-0013                  https://doi.org/10.1111/j.1365-2265.2007.02805.x
        2.  Nakamura E, Kaelin WG Jr. Recent insights into the molecular pathogenesis of pheochromocytoma and   16.  Amar L, Lussey-Lepoutre C, Lenders JW et al. Recurrence or new tumors after complete resection of
          paraganglioma. Endocr Pathol 2006;17:97-106. https://doi.org/10.1385/EP:17:2:97  pheochromocytomas and paragangliomas: A systematic review and meta-analysis. Eur J Endocrinol
        3.  Benn DE, Robinson BG. Genetic basis of pheochromocytoma and paraganglioma. Best Pract Res Clin   2016;175:R135-45. https://doi.org/10.1530/EJE-16-0189
          Endocrinol Metab 2006;20:435-50. https://doi.org/10.1016/j.beem.2006.07.005  17.  Plouin PF, Amar L, Dekkers OM et al. European Society of Endocrinology clinical practice guideline for
        4.  Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheo-  long-term followup of patients operated on for a pheochromocytoma or a paraganglioma. Eur J Endocrinol
          chromocytoma. J Clin Endocrinol Metab 2004;89:479-91. https://doi.org/10.1210/jc.2003-031091  2016;174:G1-0. https://doi.org/10.1530/EJE-16-0033
        5.  Lenders JW, Eisenhofer G, Mannelli M et al. Pheochromocytoma. Lancet 2005;366:665-75.   18.  Eisenhofer G, Goldstein DS, Walther MM et al. Biochemical diagnosis of pheochromocytoma: How
          https://doi.org/10.1016/S0140-6736(05)67139-5         to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003b;88:2656-66.
        6.  Scholz T, Eisenhofer G, Pacak K et al. Current treatment of malignant pheochromocytoma. J Clin Endocrinol   https://doi.org/10.1210/jc.2002-030005
          Metab 2007;92:1217-25. https://doi.org/10.1210/jc.2006-1544  19.  Algeciras-Schimnich A, Preissner CM, Young WF Jr et al. Plasma chromogranin A or urine fractionated
        7.  Lenders JW, Duh QY, Eisenhofer G et al. Pheochromocytoma and paraganglioma: An endocrine society   metanephrines followup testing improves the diagnostic accuracy of plasma fractionated metanephrines for
          clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915-42. https://doi.org/10.1210/  pheochromocytoma. J Clin Endocrinol Metab 2008;93:91-5. https://doi.org/10.1210/jc.2007-1354
          jc.2014-1498                                       20.  Timmers HJ, Pacak K, Huynh TT et al. Biochemically silent abdominal paragangliomas in patients with
        8.  Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk   mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab 2008;93:4826-32.
          of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab   https://doi.org/10.1210/jc.2008-1093
          2005b;90:2110-6. https://doi.org/10.1210/jc.2004-1398  21.  Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C et al. Imaging workup for screening of paraganglioma
        9.  Plouin PF, Gimenez-Roqueplo AP. Initial workup and long-term followup in patients with pheo-  and pheochromocytoma in SDHx mutation carriers: A multicenter prospective study from the PGL.EVA
          chromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 2006a;20:421-34.   Investigators. J Clin Endocrinol Metab 2013;98:E162-73. https://doi.org/10.1210/jc.2012-2975
          https://doi.org/10.1016/j.beem.2006.07.004         22.  Timmers HJ, Chen CC, Carrasquillo JA et al. Staging and functional characterization of pheochromocytoma
       10.  Hamidi O, Young WF Jr, Iniguez-Ariza NM et al. Malignant pheochromocytoma and paraganglioma: 272   and paraganglioma by 18F- fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer
          patients over 55 years. J Clin Endocrinol Metab 2017;102:3296-305. https://doi.org/10.1210/  Inst 2012;104:700-8. https://doi.org/10.1093/jnci/djs188
          jc.2017-00992                                      23.  Baudin E, Habra MA, Deschamps F et al. Therapy of endocrine disease: treatment of malignant pheo-
       11.  Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and pheochromocytoma: From genetics to person-  chromocytoma and paraganglioma. Eur J Endocrinol 2014;171:R111-22. https://doi.org/10.1530/
          alized medicine. Nat Rev Endocrinol 2015;11:101-11. https://doi.org/10.1038/nrendo.2014.188  EJE-14-0113
       12.  Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem
          2014;60:1486-99. https://doi.org/10.1373/clinchem.2014.224832  r
       13.  Lenders JW, Keiser HR, Goldstein DS et al. Plasma metanephrines in the diagnosis of pheochromocytoma.   Correspondence: D Neal Rowe, Division d’urologie, Département de chirurgie, L’Hôpital d’Ottawa,
          Ann Intern Med 1995;123:101-9. https://doi.org/10.7326/0003-4819-123-2-199507150-00004  Université d’Ottawa, Ottawa (Ont.), Canada; nealrowe81@gmail.com









































       R102                                     CUAJ • Décembre 2019 • Volume 13, numéro 12
   1   2   3   4   5   6